Independent French drugmaker Servier, which is governed by a foundation, has published its 2023/24 financial year results and reflected on the major milestones of the year.
For the 2023/2024 financial year, Servier Group revenue amounted to 5.9 billion euros ($6.2 billion), an increase of 10.8% compared with 2022/2023.
Servier noted that this performance was particularly driven by 12.6% growth in worldwide sales volumes of both brand-name and generic medicines compared with 2022/2023, despite an unfavorable currency exchange impact of -3.5% (ie, -185 million euros in 2023/2024 versus -132 million euros for the previous year). However, the group has been able to align the price of its medicines with inflation in certain countries, with a positive effect of 1.7% compared with 0.6% in 2022/2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze